November 12, 2025
An appearance/semblance of market breath
Shutdown reopening path remains foggy before House-wide vote
Pre-open Signals: 4 Positive Indications and a lot of drops
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
November 12, 2025
Q3 net loss of -$1,700 or -$0.10 per share, cash position of $1.319 K and runway until 10/25
Revenue of $123 K (cost of dietary supplements sales: 112 K), accounts payable/outstanding debts to partners ($130 K to Yale University, $133 K to former employees), no clinical results, during Q3 recorded interest expense of approximately $7 K on convertible debt and approximately $4 K on insurance installment payments, recorded a 1-time offering cost loss totaling $500 K related to an anticipated offering that was not completed.Outstanding shares: 17,033,109. Ongoing Concern label still attached.
Who is wasting lipstick on this pig?
Challenging and questionable "aspects" state the obvious – a Ponzi Scheme!
Accumulated deficit to date= $103.2 M in 12 years
U.S. investors BEWARE, forewarned is forearmed?
November 11, 2025
For a government re-open; don’t get hooked, there is always a price to be paid for political dysfunction
Unfortunately, I believe we are soon to be “cruising to a bruising” i.e., markets and sector response
News: Ionis Pharmaceuticals (IONS closed +$2.91 with a -$1.45 or -2% drop aftermarket) offers $700 M Convertible Senior Notes due 2030 in a private placement. IONS also intends to grant the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the 1st date on which the notes are issued, up to an additional $70 M principal number of notes.
RMi collects, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision
Never leave an investor uninformed!
November 12, 2025
Q3 net loss of -$1,700 or -$0.10 per share, cash position of $1.319 K and runway until 10/25 Revenue of $123 K (cost of dietary supplements sales: 112 K), accounts payable/outstanding debts to partners ($130 K to Yale University, $133 K to former employees), no clinical results, during Q3 recorded interest expense of approximately $7 K on convertible debt and approximately $4 K on insurance installment payments, recorded a 1-time offering cost loss totaling $500 K related to an anticipated offering that was not completed.Outstanding shares: 17,033,109. Ongoing Concern label still attached. Who is wasting lipstick on this pig? Challenging and questionable "aspects" state the obvious – a Ponzi Scheme! Accumulated deficit to date= $103.2 M in 12 years U.S. investors BEWARE, forewarned is forearmed?
October 26, 2025
A sector catalyst Novartis NVS) has agreed to buy Avidity Biosciences (RNA) closed up Friday +$0.60 or +1.24% to $49.15 for about $12 billion. NVS will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Friday closing price. Avidity Biosciences is a biopharmaceutical company. RNA is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). These AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies.
October 24, 2025
ADVM is up +$0.14 or +3.349% to $4.32 ADVM's lead program, Ixo-vec, is a P3 intravitreal gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Ixo-vec is designed as a single 1-time treatment to deliver continuous and stable intraocular aflibercept levels, thereby reducing the significant patient burden associated with current chronic anti-VEGF therapies, while also potentially leading to improved vision outcomes.
59 min ago
RMi pre-open: Verisimilitude
1 hour 50 min ago
RMi Research Note: Harvard Apparatus GT (OTCQB): Broke
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
